First Round of Oregon v. Pharma. State Publishes Data and Stories. Next Up: Trade Secrets
Anger against the pharmaceutical industry is growing. A Gallup poll published in September put the industry at the bottom of the heap among 25 sectors rated annually on their popularity. Nearly 60 percent of respondents said they had a negative view of the industry. People liked government more, with 52 percent seeing bureaucracies in a negative light.
Constituent anger has fueled action in Congress. Earlier this year, the U.S. Senate Finance Committee approved the Prescription Drug Price Reduction Act of 2019. That bill, sponsored by Sens. Ron Wyden, D-Ore., and Chuck Grassley, R-Iowa, would cap out-of-pocket drug costs for seniors and penalize drug companies for raising prices faster than inflation, saving taxpayers and seniors more than $110 billion a year.
Then last week, the U.S. House passed along party lines the Lower Drug Costs Now Act of 2019, co-sponsored by dozens of Democrats, including Oregon Rep. Suzanne Bonamici. That bill would give the federal government the ability to negotiate drug prices for Medicare and create an international price index.